Could a common drug protect the brain from Alzheimer's?

NCT ID NCT05386914

Ongoing Knowledge-focused Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether sirolimus, an FDA-approved drug, can improve blood flow to the brain in healthy adults with a genetic risk for Alzheimer's disease. Researchers will use MRI scans to measure changes after 4 weeks of daily low-dose sirolimus. The study also explores how lung function relates to brain blood flow. It involves 205 cognitively normal adults aged 45-65.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus
What this could lead to: If it works, this could point toward a way to improve brain blood flow in people at risk for Alzheimer's disease.
What could go wrong: This is a very early Phase 1 study with only 4 weeks of treatment. It is not designed to test whether sirolimus prevents or treats Alzheimer's, only whether it changes blood flow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION TO DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION TO DISEASE HEALTHY VOLUNTEERS

Contacts and locations

Locations

University of Missouri-Columbia

Columbia, Missouri, 65212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.